MONTREAL, Quebec — February 11, 2026 — Leads & Copy — Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for PrVOXZOGO® (vosoritide for injection), BioMarin announced today. VOXZOGO is the only approved medicine for eligible patients with achondroplasia in Canada.
VOXZOGO is indicated to increase linear growth in children with achondroplasia (4 months of age and older) whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Achondroplasia, the most common form of dwarfism, affects about 1 in 25,000 live births. It is caused by a gain-of-function pathogenic variant in the gene that encodes fibroblast growth factor receptor 3 (FGFR3), leading to impaired endochondral ossification.
VOXZOGO®, a C-type natriuretic peptide analogue, is the only pharmacological treatment available in Canada that has been demonstrated to improve body proportionality and increase growth velocity versus placebo in patients with achondroplasia.
The treatment, first approved by the U.S. Food and Drug Administration (FDA) in 2021 and later by the European Medicines Agency (EMA), acts at the level of the intracellular signaling pathway downstream of the fibroblast growth factor receptor 3 (FGFR3) gene mutation, promoting endochondral ossification.
According to Dr. Peter Kannu, Paediatrician and Clinical Geneticist, University of Alberta, the approval of VOXZOGO in Canada marks a transformative moment for children and families living with achondroplasia. Kannu said that for the first time, there is a therapy that directly targets the underlying biology of the condition, representing scientific progress and real hope for families.
Marie-Josee Toutounji, Medical Director, Canada, at BioMarin, said Health Canada’s authorization of VOXZOGO is a significant milestone for the achondroplasia community in Canada, and another step forward in BioMarin’s commitment to increase access to this therapy for patients and their families.
The results of the 111-301 study showed that VOXZOGO® was well tolerated. The most common adverse event related to its use was injection site reaction. The majority of events in the Phase 2 or 3 clinical studies were mild or moderate in severity.
BioMarin, founded in 1997 and based in San Rafael, California, is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has eight commercial therapies and a clinical and preclinical pipeline. BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
VOXZOGO® Product Monograph. BioMarin Pharmaceutical (Canada) Inc.
Savarirayan R, et al. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol. 2025;21:314–324.
Savarirayan R, et al. Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. Med. 2025;6(5):100566.
Source: BioMarin
